Encouraging Data on J&J's Simponi (Zacks.com)
Johnson and Johnson (NYSE: JNJ - News) recently presented long-term data from two phase III clinical trials of Simponi (golimumab), carried out on rheumatoid arthritis (RA) patients. It was observed that patients taking Simponi...


